Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis Following Revascularization of the Superficial Femoral Artery (SFA)

NCT00518284 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00518284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00518284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis Following Revascularization of the Superficial Femoral Artery (SFA)
Lead sponsor
Celgene Corporation
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2008
Completion date
September 30, 2009
Enrollment
6 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

vascular disease, peripheral